Cerebain Biotech Presents Update on Medical Device Research

- September 14th, 2016

Cerebain Biotech (OTCQB: CBBT) today announced that the executive team of Cerebain Biotech Corp. is very pleased to provide an update on the progress of its medical device research and development made over the last year and an outlook of 2017.

COSTA MESA, Calif.–(BUSINESS WIRE)–Cerebain Biotech (OTCQB: CBBT) today announced that the executive team of Cerebain Biotech Corp. is very pleased to provide an update on the progress of its medical device research and development made over the last year and an outlook of 2017.

  • In April 2016, we announced our intention to seek FDA approval in
    conjunction with the development and testing of our medical device for
    the treatment of Alzheimer’s and Dementia. We have reached a decisive
    point in our research and are planning to commence development of the
    device.
  • In May of 2016, we relocated our corporate headquarters from Dallas,
    Texas into the heart of Orange County in Costa Mesa, California. The
    decision to relocate was driven by the Company’s plan to seek FDA
    approval for our medical device for the treatment of Alzheimer’s and
    Dementia.
  • In June 2016, we signed a Memorandum of Understanding with the
    Department of Neurodegenerative Diseases, Mossakowski Medical Research
    Centre in Poland. The purpose of the Memorandum of Understanding is to
    commence testing of Cerebain’s Medical Device once development is
    completed.
  • The following summarizes Cerebain’s strategic plan for maximizing
    shareholder value over the coming months:

– Allocate resources to facilitate FDA strategy as it relates to further
research and testing of Cerebain’s existing technology.

– Design a surgical manual to be used by doctors and clinicians for the
purpose of implanting our medical device.

– Provide additional administrative and financial support to our
scientists to leverage their time to advance our technologies as we near
clinical trials.

Eric Clemons, President of Cerebain, stated “We would like to offer a
heartfelt thank you to each and every shareholder: past, current, and
future for your unwavering support of our company and for also taking
the time to read this important shareholder update. We are extremely
excited to continue to move forward with our development plan and to do
everything in our power to eradicate Alzheimer’s disease while adding to
shareholder value.”
About Cerebain Biotech Corp.
Cerebain Biotech (OTCQB: CBBT) is a development-stage medical device
company focused on the creation and clinical development of a minimally
invasive implantable device and a synthetic drug solution. The device
leverages the clinically observable, positive impact that omentum
stimulation has on cognitive function as related to dementias, and in
particular, Alzheimer’s disease. The corporate vision is based on these
positive clinical observations.
Forward Looking Statements
This news release contains certain “forward- looking statements.”
Forward-looking statements are based on current expectations and
assumptions and are inherently subject to risks and uncertainties, some
of which cannot be predicted or quantified, and many of which are beyond
the Company’s control. The forward-looking statements are also
identified through the use of words “believe,” enable,” “may,” “will,”
“could,” “intends,” “estimate,” “anticipate,” “plan,” “predict”
“probable,” “potential,” “possible,” “should,” “continue,” and other
words of similar meaning. Actual results could differ materially from
these forward-looking statements as a result of a number of risk factors
detailed in the Company’s reports filed with OTC Markets. Given these
risks and uncertainties, investors are cautioned not to place undue
reliance on such forward-looking statements and no assurances can be
given that such statements will be achieved.

Leave a Reply